Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial

Puntos clave

• The study reports improved tumor response when immunochemotherapy is administered at specific times of the day, highlighting the influence of biological rhythms.
• Increased tumor response rates were noted, with a remarkable 30% increase compared to traditional schedules within a 12-week timeframe.
• Conducted as a randomized phase 3 trial, this analysis involved patients receiving treatment based on circadian timing—day versus night administration.
• Findings suggest that aligning treatment with circadian rhythms supports improved outcomes, promoting further investigation into timing strategies.